The New 3rd Board: a boon to the Chinese OTC market
The New 3rd Board: a boon to the Chinese OTC mark...
Our View - Issue VIII, September 2015
In this issue of “Our view” we delve into some of the issues regarding how Shanghai’s emerging ‘New 3rd Board’ has been affecting M&A. Points of note include: a fundamental shift in China’s OTC capital markets and how small and mid-sized firms are availing of the various opportunities how Shanghai’s New 3rd Board is emerging as an alternative listing option, creating new challenges for inbound M&A the relatively high index levels being used as a benchmark by some China firms in deal negotiations in respect to valuations.
© 2024 KPMG Huazhen LLP, a People's Republic of China partnership, KPMG Advisory (China) Limited, a limited liability company in Chinese Mainland, KPMG, a Macau (SAR) partnership, and KPMG, a Hong Kong (SAR) partnership, are member firms of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.
The KPMG name and logo are trademarks used under license by the
independent member firms of the KPMG global organisation.
For more detail about the structure of the KPMG global organisation please visit https://kpmg.com/governance.